Yamaguchi, Toshifumi
Takashima, Atsuo http://orcid.org/0000-0002-8456-1248
Nagashima, Kengo
Kumagai, Koshi
Yamada, Tatsuya
Terashima, Masanori
Yabusaki, Hiroshi
Nishikawa, Kazuhiro
Tanabe, Kazuaki
Yunome, Gen
Kawachi, Yasuyuki
Yamada, Takanobu
Fukagawa, Takeo
Kinoshita, Takahiro
Watanabe, Masaya
Ishiyama, Koshiro
Inoue, Kentaro
Boku, Narikazu
Article History
Received: 19 October 2022
Accepted: 31 December 2022
First Online: 25 January 2023
Declarations
:
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent or substitute for it was obtained from all patients for being included in the study.
: Dr. Kengo Nagashima reports personal fees from Fujimoto Pharmaceutical Corporation, ENJU Pharmaceutical Co., Ltd, Toray Industries, Inc and Kowa Company, Ltd, outside the submitted work. Dr. Masanori Terashima reports personal fees from Taiho, Chugai, Ono pharmaceutical, BMS, Yakult Honsha, Takeda Pharmaceutical, Eli Lilly Japan, Pfizer Japan, Daiichi Sankyo, Johnson and Johnson, Medtronic Japan, Intuitive Surgical Japan and Olympus, outside the submitted work. Dr. Kazuhiro Nishikawa reports personal fees from Eli Lilly, personal fees from EA Pharma, Ono, and Bristol-Myers Squibb, outside the submitted work. Dr. Narikazu Boku reports personal fees from Taiho and Ono, Taiho, Daiichi Sankyo and Bristol-Myers Squibb, outside the submitted work. All remaining authors have declared no conflicts of interest.
Free to read: This content has been made available to all.